A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroids
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms AD Up
- Sponsors AbbVie
- 05 Dec 2019 NCT reports planned patient number 810 whereas Eudra reports 890, kept as per Eudra since it gives higher number.
- 29 Oct 2019 Planned End Date changed from 7 Aug 2022 to 8 Aug 2022.
- 29 Oct 2019 Planned primary completion date changed from 7 Aug 2022 to 20 Mar 2020.